Umeå universitets logga

umu.sePublikationer
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
Alternativa namn
Publikationer (10 of 52) Visa alla publikationer
Kristiansen, M., Holmlund, P., Linden, C., Eklund, A. & Jóhannesson, G. (2024). Author response: deficient optic nerve sheath occlusion in ntg patients: optic nerve damage due to translaminar pressure imbalance, glymphatic failure, or both? [Letter to the editor]. Investigative Ophthalmology and Visual Science, 65(5), Article ID 19.
Öppna denna publikation i ny flik eller fönster >>Author response: deficient optic nerve sheath occlusion in ntg patients: optic nerve damage due to translaminar pressure imbalance, glymphatic failure, or both?
Visa övriga...
2024 (Engelska)Ingår i: Investigative Ophthalmology and Visual Science, ISSN 0146-0404, E-ISSN 1552-5783, Vol. 65, nr 5, artikel-id 19Artikel i tidskrift, Letter (Övrigt vetenskapligt) Published
Ort, förlag, år, upplaga, sidor
Association for Research in Vision and Ophthalmology (ARVO), 2024
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-224851 (URN)10.1167/iovs.65.5.19 (DOI)38717422 (PubMedID)2-s2.0-85192594501 (Scopus ID)
Tillgänglig från: 2024-06-11 Skapad: 2024-06-11 Senast uppdaterad: 2024-06-13Bibliografiskt granskad
Rasmuson, E., Linden, C., Lundberg, B. & Jóhannesson, G. (2024). Changes in intraocular pressure during the first 24 h after transscleral cyclophotocoagulation. Acta Ophthalmologica
Öppna denna publikation i ny flik eller fönster >>Changes in intraocular pressure during the first 24 h after transscleral cyclophotocoagulation
2024 (Engelska)Ingår i: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]

Aims: To estimate the changes in intraocular pressure (IOP) during the first 24 h after transscleral cyclophotocoagulation (TCP).

Methods: A prospective single-centre study, where patients with glaucoma destined for treatment with TCP were asked for participation. The IOP was measured prior to TCP and at 1, 2, 4, 6 and 24 h post-TCP. An IOP spike was defined as an elevation of IOP of ≥5 mmHg compared with baseline. The visual acuity (VA) was examined at baseline and after 24 h.

Results: The mean IOP prior to TCP in 58 eyes of 58 patients was 26.2 (±8.9 SD) mmHg. Twenty-three eyes (40%) experienced an IOP spike at some examination timepoint during the first 24 h. The mean value of the IOP spike was 12.1 (±6.9) mmHg. Fifty-six per cent of the eyes with pseudoexfoliation glaucoma (PEXG) experienced an IOP spike, and 16% had an IOP spike ≥20 mmHg. The IOP was significantly reduced at the 24 h examination by 8.1 (±7.8) mmHg (n = 58). The VA 24 h after TCP was unchanged compared with baseline.

Conclusion: Clinically significant IOP spikes were common in the first 24 h post-TCP. Almost one in five eyes had an increase of 10 mmHg and in almost one in 10 eyes, the IOP increase was 20 mmHg or higher. Eyes with PEXG had a higher occurrence of IOP spikes and displayed a greater magnitude of IOP elevation. Prophylactic post-operative IOP-lowering medication should be considered to prevent further glaucoma damage.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2024
Nyckelord
glaucoma, glaucoma treatment, intraocular pressure, laser treatment, prospective study, transscleral cyclophotocoagulation
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-221046 (URN)10.1111/aos.16652 (DOI)2-s2.0-85184467199 (Scopus ID)
Forskningsfinansiär
Knut och Alice Wallenbergs StiftelseRegion Västerbotten
Tillgänglig från: 2024-02-21 Skapad: 2024-02-21 Senast uppdaterad: 2024-02-21
Jóhannesson, G., Stille, U., Taube, A. B., Karlsson, M., Kalaboukhova, L., Bergström, A., . . . Lindén, C. (2024). Guidelines for the management of open-angle glaucoma: national program area eye diseases, national working group glaucoma. Acta Ophthalmologica, 102(2), 135-150
Öppna denna publikation i ny flik eller fönster >>Guidelines for the management of open-angle glaucoma: national program area eye diseases, national working group glaucoma
Visa övriga...
2024 (Engelska)Ingår i: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 102, nr 2, s. 135-150Artikel i tidskrift (Refereegranskat) Published
Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2024
Nyckelord
glaucoma, guidelines, management, Sweden
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-219315 (URN)10.1111/aos.16599 (DOI)001134659800001 ()38164112 (PubMedID)2-s2.0-85181192008 (Scopus ID)
Tillgänglig från: 2024-01-15 Skapad: 2024-01-15 Senast uppdaterad: 2024-04-30Bibliografiskt granskad
Rasmuson, E., Bengtsson, B., Linden, C., Heijl, A., Aspberg, J., Andersson-Geimer, S. & Jóhannesson, G. (2024). Long-term follow-up of laser trabeculoplasty in multi-treated glaucoma patients. Acta Ophthalmologica, 102(2), 179-185
Öppna denna publikation i ny flik eller fönster >>Long-term follow-up of laser trabeculoplasty in multi-treated glaucoma patients
Visa övriga...
2024 (Engelska)Ingår i: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 102, nr 2, s. 179-185Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To evaluate the long-term effect of laser trabeculoplasty (LTP) in patients randomized to multi-treatment in the Glaucoma Intensive Treatment Study (GITS).

Methods: Patients with untreated newly diagnosed open-angle glaucoma were treated with three intraocular pressure (IOP)-lowering substances for 1 week and then 360 degrees argon or selective LTP was performed. IOP was measured just before LTP and repeatedly during the 60-month study period. Our previous report on 12 months follow-up data revealed no effect of LTP in eyes having an IOP <15 mmHg before the laser treatment.

Results: Before LTP, the mean IOP +/- standard deviation in all 152 study-eyes of 122 multi-treated patients was 14.0 +/- 3.5 mmHg. Three eyes of three deceased patients were lost to follow-up during the 60 months. After exclusion of eyes that received increased therapy during follow-up, the IOP was significantly reduced at all visits up to 48 months in eyes with pre-LTP IOP >= 15 mmHg; 2.6 +/- 3.1 mmHg at 1 month and 1.7 +/- 2.8 mmHg at 48 months, n = 56 and 48, respectively. No significant IOP reduction was seen in eyes with pre-LTP IOP <15 mmHg. Seven eyes, i.e., <13%, with pre-LTP IOP >= 15 mmHg at baseline had required increased IOP-lowering therapy at 48 months.

Conclusion: LTP performed in multi-treated patients may provide a useful IOP reduction that is maintained over several years. This was true on a group level when the initial IOP was >= 15 mmHg, but if the pre-laser IOP was lower than that, chances of LTP success were small.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2024
Nyckelord
ALT, intraocular pressure, laser trabeculoplasty, long-term follow-up, multi-therapy, open-angle glaucoma, pseudoexfoliation glaucoma, SLT
Nationell ämneskategori
Klinisk medicin Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-206002 (URN)10.1111/aos.15718 (DOI)001001069900001 ()37278271 (PubMedID)2-s2.0-85161487517 (Scopus ID)
Forskningsfinansiär
Kronprinsessan Margaretas MinnesfondUmeå universitetLunds universitetÖgonfondenKonung Gustaf V:s och Drottning Victorias FrimurarestiftelseSveriges läkarförbundSvenska Sällskapet för Medicinsk Forskning (SSMF)Västerbottens läns landsting
Anmärkning

Originally included in thesis in manuscript form.

Tillgänglig från: 2023-03-27 Skapad: 2023-03-27 Senast uppdaterad: 2024-05-06Bibliografiskt granskad
Otmani, A., Jóhannesson, G., Brautaset, R., Tribble, J. R. & Williams, P. A. (2024). Prophylactic nicotinamide treatment protects from rotenone-induced neurodegeneration by increasing mitochondrial content and volume. Acta neuropathologica communications, 12(1), Article ID 37.
Öppna denna publikation i ny flik eller fönster >>Prophylactic nicotinamide treatment protects from rotenone-induced neurodegeneration by increasing mitochondrial content and volume
Visa övriga...
2024 (Engelska)Ingår i: Acta neuropathologica communications, E-ISSN 2051-5960, Vol. 12, nr 1, artikel-id 37Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Leber’s hereditary optic neuropathy (LHON) is driven by mtDNA mutations affecting Complex I presenting as progressive retinal ganglion cell dysfunction usually in the absence of extra-ophthalmic symptoms. There are no long-term neuroprotective agents for LHON. Oral nicotinamide provides a robust neuroprotective effect against mitochondrial and metabolic dysfunction in other retinal injuries. We explored the potential for nicotinamide to protect mitochondria in LHON by modelling the disease in mice through intravitreal injection of the Complex I inhibitor rotenone. Using MitoV mice expressing a mitochondrial-tagged YFP in retinal ganglion cells we assessed mitochondrial morphology through super-resolution imaging and digital reconstruction. Rotenone induced Complex I inhibition resulted in retinal ganglion cell wide mitochondrial loss and fragmentation. This was prevented by oral nicotinamide treatment. Mitochondrial ultrastructure was quantified by transition electron microscopy, demonstrating a loss of cristae density following rotenone injection, which was also prevented by nicotinamide treatment. These results demonstrate that nicotinamide protects mitochondria during Complex I dysfunction. Nicotinamide has the potential to be a useful treatment strategy for LHON to limit retinal ganglion cell degeneration.

Ort, förlag, år, upplaga, sidor
BioMed Central (BMC), 2024
Nyckelord
Mitochondria, Neurodegeneration, Nicotinamide, Optic nerve, Retina, Retina ganglion cells
Nationell ämneskategori
Neurovetenskaper Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:umu:diva-222236 (URN)10.1186/s40478-024-01724-z (DOI)1176539900001 ()38429841 (PubMedID)2-s2.0-85186470382 (Scopus ID)
Forskningsfinansiär
Vetenskapsrådet, 2022–00799Karolinska InstitutetStiftelsen Kronprinsessan Margaretas arbetsnämnd för synskadade
Tillgänglig från: 2024-03-18 Skapad: 2024-03-18 Senast uppdaterad: 2024-03-18Bibliografiskt granskad
Azuara-Blanco, A., McCorry, N., Tatham, A. J., Georgoulas, S., Founti, P., Schweitzer, C., . . . Topouzis, F. (2023). European Glaucoma Society research priorities for glaucoma care. British Journal of Ophthalmology
Öppna denna publikation i ny flik eller fönster >>European Glaucoma Society research priorities for glaucoma care
Visa övriga...
2023 (Engelska)Ingår i: British Journal of Ophthalmology, ISSN 0007-1161, E-ISSN 1468-2079Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]

Background/Aims: The goal of health research is to improve patients care and outcomes. Thus, it is essential that research addresses questions that are important to patients and clinicians. The aim of this study was to develop a list of priorities for glaucoma research involving stakeholders from different countries in Europe.

Methods: We used a three-phase method, including a two-round electronic Delphi survey and a workshop. The clinician and patient electronic surveys were conducted in parallel and independently. For phase I, the survey was distributed to patients from 27 European countries in 6 different languages, and to European Glaucoma Society members, ophthalmologists with expertise in glaucoma care, asking to name up to five research priorities. During phase II, participants were asked to rank the questions identified in phase I using a Likert scale. Phase III was a 1 day workshop with patients and clinicians. The purpose was to make decisions about the 10 most important research priorities using the top 20 priorities identified by patients and clinicians.

Results: In phase I, 308 patients and 150 clinicians were involved. In phase II, the highest-ranking priority for both patients and clinicians was € treatments to restore vision'. In phase III, eight patients and four clinicians were involved. The top three priorities were € treatments to stop sight loss', € treatments to restore vision' and € improved detection of worsening glaucoma'.

Conclusion: We have developed a list of priorities for glaucoma research involving clinicians and patients from different European countries that will help guide research efforts and investment.

Ort, förlag, år, upplaga, sidor
BMJ Publishing Group Ltd, 2023
Nyckelord
clinical trial, diagnostic tests/investigation, glaucoma, treatment medical, treatment surgery
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-217025 (URN)10.1136/bjo-2023-323648 (DOI)001094788800001 ()37923373 (PubMedID)2-s2.0-85176602136 (Scopus ID)
Tillgänglig från: 2023-11-23 Skapad: 2023-11-23 Senast uppdaterad: 2024-01-15
Barkander, A., Economou, M. A. & Jóhannesson, G. (2023). Kahook dual-blade goniotomy with and without phacoemulsification in medically uncontrolled glaucoma. Clinical Ophthalmology, 17, 1385-1394
Öppna denna publikation i ny flik eller fönster >>Kahook dual-blade goniotomy with and without phacoemulsification in medically uncontrolled glaucoma
2023 (Engelska)Ingår i: Clinical Ophthalmology, ISSN 1177-5467, E-ISSN 1177-5483, Vol. 17, s. 1385-1394Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To evaluate the 2-year efficacy and safety of Kahook dual-blade (KDB) goniotomy in patients with medically uncontrolled glaucoma.

Methods: This was a retrospective case-series study of 90 consecutive patients with primary open-angle glaucoma (POAG) or pseudoexfoliation glaucoma (PEXG) that underwent KDB goniotomy alone (KDB-alone group) or KDB goniotomy in combination with phacoemulsification (KDB-phaco group) during 2019–2020. All patients were uncontrolled on three or more medications. Surgical success was defined as an IOP reduction ≥20% and/or a reduction of one or more medications at 24 months. We also report IOP levels and number of medications from baseline to 24 months, as well as the need for further glaucoma interventions.

Results: At 24 months, mean IOP had reduced from 24.8±8.3 to 15.0±5.3 mmHg in the KDB-alone group (P<0.001) and from 22.3 ±5.8 to 13.9±3.0 mmHg in the KDB-phaco group (P<0.001). Medications had reduced from 3.5±0.6 to 3.1±0.9 in the KDB-alone group (P=0.047) and from 3.3±0.5 to 2.3±1.1 in the KDB-phaco group (P<0.001). An IOP reduction ≥20% and/or a reduction with one or more medications was achieved by 47% of eyes in the KDB-alone group and by 76% of eyes in the KDB-phaco group. Eyes with PEXG and POAG responded equally well to the success criteria. During the 24-month follow-up, additional glaucoma surgery or transscleral photocoagulation was performed in 28% of eyes in the KDB-alone group and in 12% of eyes in the KDB-phaco group.

Conclusion: In patients with medically uncontrolled glaucoma, KDB had a significant IOP-lowering effect after 24 months, but success rates were higher when KDB was performed in combination with cataract surgery compared to stand-alone treatment.

Ort, förlag, år, upplaga, sidor
Dove press, 2023
Nyckelord
Kahook dual blade, medically uncontrolled glaucoma, phacoemulsification, primary open-angle glaucoma, pseudoexfoliation glaucoma
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-209192 (URN)10.2147/OPTH.S409375 (DOI)000992915500001 ()37204995 (PubMedID)2-s2.0-85160225264 (Scopus ID)
Forskningsfinansiär
Region Jämtland HärjedalenRegion VästerbottenKnut och Alice Wallenbergs Stiftelse
Tillgänglig från: 2023-06-12 Skapad: 2023-06-12 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Gustavsson, S. T., Enz, T. J., Tribble, J. R., Nilsson, M., Lindqvist, A., Linden, C., . . . Jóhannesson, G. (2023). Nicotinamide prevents retinal vascular dropout in a rat model of ocular hypertension and supports ocular blood supply in glaucoma patients. Investigative Ophthalmology and Visual Science, 64, Article ID 34.
Öppna denna publikation i ny flik eller fönster >>Nicotinamide prevents retinal vascular dropout in a rat model of ocular hypertension and supports ocular blood supply in glaucoma patients
Visa övriga...
2023 (Engelska)Ingår i: Investigative Ophthalmology and Visual Science, ISSN 0146-0404, E-ISSN 1552-5783, Vol. 64, artikel-id 34Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

PURPOSE. To investigate whether nicotinamide (NAM) modulates retinal vasculature in glaucoma.

METHODS. This was a prospective controlled clinical trial investigating animal and human histopathology. Participants included normotensive and ocular hypertensive rats, postmortem human ocular tissue, glaucoma patients (n = 90), and healthy controls (n = 30). The study utilized histopathology, computer-assisted retinal vasculature analysis, optical coherence tomography angiography (OCTA), and NAM treatment. The main outcome measures included retinal vascular parameters in rats as assessed by AngioTool; retinal vasculature integrity in rats and humans as assessed by histopathology, antibody-staining, and ImageJ-based measurements; and retinal perfusion density (PD) and flux index in humans as assessed by OCTA.

RESULTS. A number of vessel parameters were altered in ocular hypertension/glaucoma compared to healthy controls. NAM treatment improved the retinal vasculature in ocular hypertensive rats, with an increase in mean vessel area, percentage area covered by vessels, total vessel length, total junctions, and junction density as assessed by AngioTool (all P < 0.05); vessel wall integrity as assessed by VE-cadherin antibody staining was also improved (P < 0.01). In humans, as assessed by OCTA, increases in PD in the optic nerve head and macula complete image (0.7%, P = 0.04 and 1.0%, P = 0.002, respectively) in healthy controls, and an increase in the temporal quadrant of the macula (0.7%, P = 0.02) in glaucoma patients was seen after NAM treatment.

CONCLUSIONS. NAM can prevent retinal vascular damage in an animal model of glaucoma. After NAM treatment, glaucoma patients and healthy controls demonstrated a small increase in retinal vessel parameters as assessed by OCTA.

Ort, förlag, år, upplaga, sidor
Association for Research in Vision and Ophthalmology (ARVO), 2023
Nyckelord
glaucoma, histopathology, nicotinamide, optical coherence tomography angiography, retinal vasculature
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-218131 (URN)10.1167/iovs.64.14.34 (DOI)38010699 (PubMedID)2-s2.0-85178055569 (Scopus ID)
Forskningsfinansiär
VetenskapsrådetKarolinska Institutet
Tillgänglig från: 2023-12-15 Skapad: 2023-12-15 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Kristiansen, M., Holmlund, P., Linden, C., Eklund, A. & Jóhannesson, G. (2023). Optic nerve subarachnoid space posture dependency: an MRI study in subjects with normal tension glaucoma and healthy controls. Investigative Ophthalmology and Visual Science, 64(15), Article ID 20.
Öppna denna publikation i ny flik eller fönster >>Optic nerve subarachnoid space posture dependency: an MRI study in subjects with normal tension glaucoma and healthy controls
Visa övriga...
2023 (Engelska)Ingår i: Investigative Ophthalmology and Visual Science, ISSN 0146-0404, E-ISSN 1552-5783, Vol. 64, nr 15, artikel-id 20Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: The purpose of this study was to examine the differences of optic nerve subarachnoid space (ONSAS) volume in patients with normal tension glaucoma (NTG) and healthy controls in different body positions.

Methods: Eight patients with NTG and seven healthy controls underwent magnetic resonance imaging (MRI) examinations in head up tilt (HUT) +11 degrees and head down tilt (HDT) -5 degrees positions according to a randomized protocol determining the starting position. The ONSAS volume in both body positions was measured and compared between the two groups. The results were analyzed using a generalized linear model.

Results: Between HDT and HUT, the postural ONSAS volume change was dependent on starting position (P < 0.001) and group (P = 0.003, NTG versus healthy). A subgroup analysis of those that were randomized to HUT examination first, coming directly from an upright position, showed that the patients with NTG had significantly larger positional ONSAS volume changes compared to the healthy controls; 121 ± 22 µL vs. 65 ± 37 µL (P = 0.049). Analysis of the ONSAS volume distribution showed different profiles for patients with NTG and healthy controls.

Conclusions: There was a significant difference in ONSAS volume change between patients with NTG and healthy subjects when subjected to posture changes, specifically when going from upright to head-down posture. This indicates that patients with NTG had been exposed to a lower ONSAS pressure when they came from the upright posture, which suggests an increased translaminar pressure difference in upright position. This may support the theory that NTG has a dysfunction in an occlusion mechanism of the optic nerve sheath that could cause abnormally negative ONSAS pressures in upright posture.

Nyckelord
optic nerve subarachnoid space (ONSAS), glaucoma
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-218636 (URN)10.1167/iovs.64.15.20 (DOI)38099734 (PubMedID)2-s2.0-85179765988 (Scopus ID)
Tillgänglig från: 2023-12-27 Skapad: 2023-12-27 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Barkander, A., Economou, M. & Jóhannesson, G. (2023). Outcomes of iStent inject versus kahook dual blade surgery in glaucoma patients undergoing cataract surgery. Journal of glaucoma, 32(10), e121-e128
Öppna denna publikation i ny flik eller fönster >>Outcomes of iStent inject versus kahook dual blade surgery in glaucoma patients undergoing cataract surgery
2023 (Engelska)Ingår i: Journal of glaucoma, ISSN 1057-0829, E-ISSN 1536-481X, Vol. 32, nr 10, s. e121-e128Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Précis: iStent Inject implantation (iStent) or Kahook Dual Blade goniotomy (KDB) in combination with phacoemulsification have a similar IOP-lowering effect in all stages of glaucoma, and medications are significantly reduced, especially after KDB.

PURPOSE: To compare the 2-year efficacy and safety of iStent or KDB in combination with phacoemulsification in eyes with mild to advanced open angle glaucoma.

METHODS: A retrospective chart review of 153 patients that received iStent or KDB in combination with phacoemulsification at a single center between March 2019 and August 2020. The main outcome parameters at 2 years were: (1) intraocular pressure (IOP)-reduction ≥20%, with a postoperative IOP ≤18 mm Hg, and (2) a reduction of ≥1 medication. Results were stratified by glaucoma grade.

RESULTS: After 2 years, mean IOP was reduced from 20.3±6.1 to 14.2±4.1 mm Hg in the phaco-iStent group ( P <0.001) and from 20.1±6.1 to 14.7±3.6 mm Hg in the phaco-KDB group ( P <0.001). The mean number of medications was reduced from 3.0±0.9 to 2.6±1.1 in the Phaco-iStent group ( P =0.001) and from 2.3±1.0 to 1.5±1.3 in the Phaco-KDB group ( P <0.001). Success regarding IOP-reduction ≥20% with a postoperative IOP ≤18 mm Hg was met by 46% in the phaco-iStent group and by 51% in the phaco-KDB group. A reduction of ≥1 medication was met by 32% in the phaco-iStent group and by 53% in the phaco-KDB group ( P =0.013). Eyes with mild to moderate and advanced glaucoma responded equally well to the success criteria.

CONCLUSIONS: iStent and KDB, in combination with phacoemulsification, both lowered IOP effectively in all stages of glaucoma. More medications were reduced after KDB, suggesting that it may be a more effective procedure compared with iStent.

Ort, förlag, år, upplaga, sidor
Wolters Kluwer, 2023
Nationell ämneskategori
Oftalmologi
Identifikatorer
urn:nbn:se:umu:diva-215079 (URN)10.1097/IJG.0000000000002243 (DOI)37327470 (PubMedID)2-s2.0-85172940680 (Scopus ID)
Forskningsfinansiär
Region Jämtland HärjedalenRegion VästerbottenKnut och Alice Wallenbergs Stiftelse
Tillgänglig från: 2023-10-13 Skapad: 2023-10-13 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Projekt
Neuroprotektiv behandling av glaukom - En klinisk randomiserad studie för utvärdering av nikotinamid [2019-06076_VR]; Umeå universitet
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0003-0218-4563

Sök vidare i DiVA

Visa alla publikationer